Skip to content
Open access

Subpocket-Aware Fragment-Based Docking Pipeline for Kinase Ligand Design: Methodology and a PKA Case Study

Oct 2026 · Journal of Chemical Information and Modeling · Vol 66, pp. 13397 - 13412 · 0 citations · 63 references
Medicine

TL;DR

An efficient exploration strategy that integrates subpocket-guided fragment growing with template docking with structure-informed guidance can transform fragment-based design into a scalable route for discovering novel kinase inhibitors is presented.

Abstract

Protein kinases regulate signal transduction through phosphorylation, and their dysregulation drives diseases like cancer, autoimmune disorders, and Alzheimer’s, making them key drug targets. Fragment-based drug design offers a powerful route to kinase inhibitors but often neglects kinase-specific structural insights. While KinFragLib, a library consisting of 7486 fragments derived from kinase-ligand complexes, provides a rich resource, exhaustive recombination of its fragments is computationally demanding. Here, we present an efficient exploration strategy that integrates subpocket-guided fragment growing with template docking to navigate this vast chemical space. Our automated pipeline prioritizes kinase-specific structural information, enabling targeted generation of chemically diverse ligands. Applied to the PKA kinase, the approach produced 33758 candidate molecules with promising docking scores, of which 15 were synthesized. Seven molecules reduced kinase activity by more than 50% at an inhibitor concentration of 100 μM, and five of these compounds also showed promising efficacy at a concentration of 10 μM. The IC50 determination ultimately revealed that five of the molecules were effective in the two- to three-digit nanomolar range. Crystallographic validation confirmed the predicted binding mode of the most potent compound. This methodology demonstrates how structure-informed guidance can transform fragment-based design into a scalable route for discovering novel kinase inhibitors.

Read PDF

Similar papers

Open access Sep 2026

Computational de novo discovery of novel mTOR inhibitors using recurrent neural networks and integrated in silico approaches including docking and DFT

A Recurrent Neural Network-based de novo drug design approach was employed to discover novel mTOR inhibitors, and S000031 emerged as the most promising candidate due to its superior binding affinity, structural novelty, and electronic characteristics.

Amisha Bisht, Sanjay Kumar, Subhash Chandra · 0 citations
Open access Oct 2026

Polypharmacological target-aware molecule generation

This work reformulates multitarget drug design as a sequence-based generation task and introduces PolyTamGen, an end-to-end autoregressive framework that improves joint success rates over representative baselines while maintaining high chemical validity and diversity.

Ke-Han Wu, Wei Zhang, Han Guo et al. · 0 citations
Review Open access Sep 2026

Drug Repositioning in Kinase Inhibitor Discovery for Cancer Therapy

Repurposing of existing drugs has emerged as a time- and cost-effective strategy in oncology drug discovery. Given the critical role of dysregulated kinase signaling in cancer, kinase-focused repurposing strategies have attracted considerable interest. This approach encompasses both “target hopping” between different k...

Qian-Ran Sun, Xiao-Cong Pang, Wen-Wu Liu · 0 citations
Oct 2026

A fine-tuning-guided virtual screening workflow identifies cell-active small-molecule hits targeting Gq-mediated signaling.

A prioritization workflow that combines target-specific fine-tuning of a pretrained drug-target interaction model, pharmacophore filtering, and structure-based docking to identify candidate Gq-modulating compounds from commercial libraries is developed.

Zi-Yang Wu, Xin Chen, Hang Su et al. · 0 citations
Sep 2026

Ligand-based pharmacophore modeling and molecular dynamics driven discovery of novel MEK1 inhibitors targeting KRAS signalling pathway.

The KRAS oncogene, which plays a crucial role in numerous human malignancies, remains a significant challenge. It is amongst the most mutated oncogenes within human cancers, specifically in pancreatic, colorectal, and non-small cell lung cancers, where it is a key driver of cancer initiation and growth. Despite its imp...

Krishna Kalaskar, R. Alavala · 0 citations
Oct 2026

Generative design and computational characterization of pyrazoline-based EGFR kinase inhibitor candidates.

The epidermal growth factor receptor (EGFR) is an established therapeutic target in breast, colorectal, and non-small cell lung cancers, and pyrazoline-containing scaffolds have been repeatedly reported as EGFR inhibitors. This study combined generative machine learning with physics-based modelling to design and comput...

Kumud P. Bhendarkar, P. Khedekar, M. Islam et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.